Inotek Pharmaceuticals Corp.
Inotek Pharmaceuticals Corp. is listed today as Rocket Pharmaceuticals, Inc.: market value, financials and filings are on its company page.
Funding rounds
1 counted as startup funding. Open the number of investors for the round's details.
| Month | Raised | Raise | Size | Investors | Sold | Filing |
|---|---|---|---|---|---|---|
| Jun 2010 | $24 M | No. 1 | $10 to $50 million | equity | SEC |
How it makes money#
What its filings and its own website say, sentence by sentence, each with its source.
Inotek Pharmaceuticals Corp. chose not to state its revenue in its newest notice of a funding round (Jul 2011).
SEC Form D · Jul 2011
The industry group it chose in its notices: Pharmaceuticals.
SEC Form D · Jul 2011
Products and services#
No products or services of Inotek Pharmaceuticals Corp. are on record.
Investors#
24 named in official filings. Open an investor to see everything it has backed.
| Investor | Kind | Amount | Round | Role | Source |
|---|---|---|---|---|---|
| Care Capital III LLC | Fund or asset manager | not stated | not stated | Held Series AA preferred stock, 10% owner (Form 3, 2015) | SEC Form 3 |
| Care Capital II LLC | Fund or asset manager | not stated | not stated | Held Series AA preferred stock, 10% owner (Form 3, 2015) | SEC Form 3 |
| Care Capital Investments III L.P. | Fund or asset manager | not stated | not stated | Held Series AA preferred stock, 10% owner (Form 3, 2015) | SEC Form 3 |
| Care Capital Investments II LP | Fund or asset manager | not stated | not stated | Held Series AA preferred stock, 10% owner (Form 3, 2015) | SEC Form 3 |
| Care Capital Offshore Investments III LP | Fund or asset manager | not stated | not stated | Held Series AA preferred stock, 10% owner (Form 3, 2015) | SEC Form 3 |
| Care Capital Offshore Investments II LP | Fund or asset manager | not stated | not stated | Held Series AA preferred stock, 10% owner (Form 3, 2015) | SEC Form 3 |
| Devon Park Associates, LLC | Other | not stated | not stated | Held Series AA preferred stock, 10% owner (Form 3, 2015) | SEC Form 3 |
| Devon Park Associates, L.P. | Fund or asset manager | not stated | not stated | Held Series AA preferred stock, 10% owner (Form 3, 2015) | SEC Form 3 |
| Devon Park Bioventures LP | Venture capital | not stated | not stated | Held Series AA preferred stock, 10% owner (Form 3, 2015) | SEC Form 3 |
| MedImmune Ventures, Inc. | Venture capital | not stated | not stated | Held Series AA preferred stock, 10% owner (Form 3, 2015) | SEC Form 3 |
| Paul G. Howes | Person | not stated | not stated | Held Series X preferred stock, director (Form 3, 2015) | SEC Form 3 |
| Pitango G.C. Capital Holdings Ltd. | Fund or asset manager | not stated | not stated | Held Series AA preferred stock, 10% owner (Form 3, 2015) | SEC Form 3 |
| Pitango V.C. Fund IV, L.P. | Fund or asset manager | not stated | not stated | Held Series AA preferred stock, 10% owner (Form 3, 2015) | SEC Form 3 |
| Pitango Venture Capital Fund IV, L.P. | Venture capital | not stated | not stated | Held Series AA preferred stock, 10% owner (Form 3, 2015) | SEC Form 3 |
| Pitango Venture Capital Principals Fund IV, L.P. | Venture capital | not stated | not stated | Held Series AA preferred stock, 10% owner (Form 3, 2015) | SEC Form 3 |
| Rho Capital Partners Verwaltungs Gmbh | Fund or asset manager | not stated | not stated | Held Series AA preferred stock, 10% owner (Form 3, 2015) | SEC Form 3 |
| Rho Management Ventures IV LLC | Venture capital | not stated | not stated | Held Series AA preferred stock, 10% owner (Form 3, 2015) | SEC Form 3 |
| Rho Ventures IV-A, L.P. | Venture capital | not stated | not stated | Held Series AA preferred stock, 10% owner (Form 3, 2015) | SEC Form 3 |
| Rho Ventures IV Gmbh & Co Beteiligungs KG | Venture capital | not stated | not stated | Held Series AA preferred stock, 10% owner (Form 3, 2015) | SEC Form 3 |
| Rho Ventures IV Holdings LLC | Venture capital | not stated | not stated | Held Series AA preferred stock, 10% owner (Form 3, 2015) | SEC Form 3 |
| Rho Ventures IV LP | Venture capital | not stated | not stated | Held Series AA preferred stock, 10% owner (Form 3, 2015) | SEC Form 3 |
| Rho Ventures IV QP LP | Venture capital | not stated | not stated | Held Series AA preferred stock, 10% owner (Form 3, 2015) | SEC Form 3 |
| Rudolph Baumgartner | Person | not stated | not stated | Held Series X preferred stock (Form 3, 2015) | SEC Form 3 |
| William K. McVicar | Person | not stated | not stated | Held Series X preferred stock (Form 3, 2015) | SEC Form 3 |
Largest shareholders today
Institutions holding Rocket Pharmaceuticals, Inc. shares, as of Sep 30, 2026.
- RTW Investments, LP$47 M15.84%
- BlackRock, Inc.$35 M11.79%
- Millennium Management LLC$13 M4.32%
- Citigroup Inc$12 M4.13%
- Newtyn Management, LLC$11 M3.58%
- Maverick Capital LTD$10 M3.44%
- Vanguard Capital Management LLC$10 M3.43%
- Marshall Wace, LLP$9 M3.15%
- Monaco Asset Management SAM$8 M2.62%
- Federated Hermes, Inc.$7 M2.26%
- Rosalind Advisors, Inc.$6 M1.97%
- State Street Corp$5 M1.68%
- Goldman Sachs Group Inc$5 M1.64%
- Geode Capital Management, LLC$5 M1.54%
- AQR Capital Management LLC$4 M1.50%
As of Sep 30, 2026
Executives and directors
As the company named them in its notices. Directors of a funded startup are often partners of its investors.
| Name | Role | Named in |
|---|---|---|
| James G. Ham, III | Chief Financial Officer | Jul 2011 |
| Paul G. Howes | President & Chief Executive Officer | Jul 2011 |
| Rudolf A. Baumgartner, MD | Executive Vice President, Chief Medical Officer | Jul 2011 |
| William K. McVicar, Ph.D. | Executive Vice President, Chief Scientific Offier | Jul 2011 |
| "Argeris (""Jerry"")" N. Karabelas, PhD | Director | Jul 2011 |
| Atul N. Saran | Director | Jul 2011 |
| Ittai N. Harel | Director | Jul 2011 |
| John N. Leaman | Director | Jul 2011 |
| Martin N. Vogelbaum | Director | Jul 2011 |
| Michael D. Loberg, PhD | Director | Jul 2011 |
| Paul G. Howes | President & Chief Executive Officer | Jul 2011 |
| Ittai Flanagan Harel | Director | Jun 2010 |
| John Flanagan Leaman | Director | Jun 2010 |
| Maggie Flanagan LeFlore, PhD | Director | Jun 2010 |
Went public since 2015. Its SEC number is that of a company listed on a stock exchange.